Company Profile

Bondwell Technologies Inc
Profile last edited on: 4/17/2023      CAGE: 7XKN6      UEI: W1ANWG7S7FK9

Business Identifier: Immobilization and stabilization of biocatalysts for efficient pharmaceutical manufacturing
Year Founded
2017
First Award
2019
Latest Award
2022
Program Status
Active
Popularity Index
Is this YOUR Company?
Ensure accuracy and completeness of YOUR Company Profile by completing the brief Survey Instrument attached
Do you know about this Awardees?
Let us encourage you to provide any data which would enhance the completeness of this firm's profile.

Location Information

501 Graham Road
College Station, TX 77845
   (210) 324-9657
   N/A
   www.bondwelltech.com
Location: Single
Congr. District: 17
County: Brazos

Public Profile

Coming out of work undertaken by Texas A&M University scientists, Bondwell Technologies is structured around bringing to use condition a biomaterial-based platform technology that allows utilization of the natural ability of proteins -- molecular tools required for every natural process and having relavance across various fields: energy, environment, and medicine. Recently, Bondwell Technologies announcedt hat it had been selected as a TRISH investigator under the Biomedical Research Advances for Space Health program. Part of NASA's Human Research Program’s research activity, TRISH is focused on engaging a wide variety of partners in solving some of the challenges of keeping humans healthy in deep space.

Extent of SBIR involvement

User Avatar

Synopsis: Awardee Business Condition

Employee Range
5-9
Revenue Range
.5M-1M
VC funded?
Yes
Public/Private
Privately Held
Stock Info
----
IP Holdings
N/A

Awards Distribution by Agency

Most Recent SBIR Projects

Year Phase Agency Total Amount
2022 2 NIH $1,888,465
Project Title: A High-Efficiency, Low-Cost, Single-Use Purification Technology for Therapeutic Antibody Manufacturing
2022 1 NIH $275,766
Project Title: Novel biomaterial for enantiomer separation
2021 1 NSF $235,506
Project Title: A high-efficiency filter for endotoxin removal
0 1 NIH $275,384
Project Title: Novel, Targeted Method for Bacteriophage Purification

Key People / Management

  David Howell -- Founder, President and CEO

  Sarah E Bondos -- Chief Scientific Officer

  Kristin Howell -- Founder

  Lauren Kustigian

  Christi Parham

Company News

There are no news available.